Voniza Tablet 10 mg

About Voniza Tablet 10 mg

Voniza Tablet Uses

• Treatment of gastroesophageal reflux disease (GERD) and reflux esophagitis.
• Management of gastric and duodenal ulcers including those caused by Helicobacter pylori infection.
• Prevention and treatment of ulcers associated with aspirin and nonsteroidal anti-inflammatory drug (NSAID) use.
• Long-term acid suppression for chronic acid-related disorders and erosive esophagitis.
• Adjunctive therapy in Helicobacter pylori eradication regimens.

Voniza Tablet Benefits

• Potent and rapid acid suppression compared to traditional proton pump inhibitors.
• Maintains stable intragastric pH over 24 hours providing sustained symptom relief.
• Once-daily dosing improves patient compliance and convenience.
• Effective in patients with incomplete response to conventional acid suppressors.
• Well-tolerated with favorable safety profile for long-term use.

What Experts Say

Vonoprazan is a novel potassium-competitive acid blocker (PCAB) that functions distinctly from traditional proton pump inhibitors. It competitively inhibits the binding of potassium ions to the H+/K+-ATPase proton pump located on gastric parietal cells. This mechanism of action is independent of acid activation allowing stronger and more sustained acid suppression. Vonoprazan demonstrates superior efficacy in achieving sustained intragastric pH control compared to conventional PPIs.

Pharmacokinetically, vonoprazan exhibits rapid absorption with peak plasma concentrations occurring within 1 to 2 hours of oral administration. The drug shows higher bioavailability than traditional PPIs with food having minimal impact on absorption. Hepatic metabolism via CYP3A4 produces inactive metabolites. The elimination half-life ranges from 1.5 to 2.5 hours but the drug maintains prolonged acid suppression due to its accumulation in gastric parietal cells. Renal excretion accounts for the majority of elimination.

Clinical efficacy studies demonstrate superior healing rates for gastric and duodenal ulcers compared to omeprazole and lansoprazole. Vonoprazan achieves faster symptom relief and superior healing in erosive esophagitis. The drug proves particularly valuable for patients who have failed conventional PPI therapy. Long-term follow-up data indicates sustained safety and efficacy over extended treatment periods. Helicobacter pylori eradication rates improve when vonoprazan is incorporated into triple or quadruple therapy regimens.

Drug Class

• Potassium-Competitive Acid Blocker (PCAB)

Packaging and Quantity

• Blister strip containing 14 tablets of 20 mg each or strip containing 14 tablets of 10 mg each.

When Not to Use Voniza

• Known hypersensitivity to vonoprazan or any component of the formulation.
• Severe hepatic impairment or advanced liver disease.
• First trimester of pregnancy unless clearly necessary.
• Suspected gastric malignancy until exclusion is confirmed.
• Severe renal impairment requiring dose adjustment.

Voniza Tablet 10 mg formula

• Vonoprazan

Available forms

• Tablets

How to use Voniza Tablet 10 mg?

• Take orally once daily as directed by your healthcare provider.
• Typical dose for GERD and ulcer treatment is 20 mg once daily.
• Take preferably before meals to enhance absorption.
• Swallow tablet whole with water without crushing or chewing.
• Continue treatment for the prescribed duration even if symptoms improve.
• For Helicobacter pylori eradication, take as part of combination therapy per doctor instructions.

Drug Interactions

Voniza may interact with various medications affecting efficacy or safety:

• CYP3A4 substrates: Vonoprazan may increase levels of medications metabolized by CYP3A4; monitor for increased toxicity.
• Medications requiring acidic pH: Absorption of drugs dependent on gastric acidity may be reduced; separate dosing times.
• Atazanavir: Vonoprazan may reduce absorption; concurrent use is not recommended.
• Clopidogrel: May reduce activation of clopidogrel; consider alternative acid suppressors.

Risks and warnings

• Hepatic impairment: Severe liver disease is a contraindication; use cautiously in mild to moderate impairment.
• Renal dysfunction: Use with caution in moderate to severe kidney disease; dose adjustment may be needed.
• Hypomagnesemia: Long-term acid suppression may reduce magnesium absorption; monitor levels periodically.
• Gastric malignancy: Symptomatic improvement may mask gastric cancer symptoms; investigate alarm symptoms appropriately.
• Pregnancy: Limited safety data in early pregnancy; use only if benefits clearly outweigh risks.
• Breastfeeding: Vonoprazan passes into breast milk; use with caution during lactation.
• Long-term safety: Chronic acid suppression may affect nutrient absorption and B12 levels over extended periods.

Voniza Tablet Side Effects

Most side effects are mild and transient with continued use. Following are commonly reported adverse effects:

• Headache.
• Diarrhea or constipation.
• Abdominal discomfort or pain.
• Nausea.
• Dizziness or lightheadedness.

Serious side effects requiring immediate medical attention:

• Severe allergic reaction with rash, angioedema, or anaphylaxis.
• Severe hepatotoxicity or liver dysfunction.
• Hypomagnesemia with prolonged use.
• Interstitial nephritis or acute kidney injury.

Storage Conditions

• Store at room temperature below 30 degrees Celsius.
• Keep away from direct sunlight and excessive heat.
• Protect from moisture in a tightly sealed container.
• Keep in original blister strip or tablet container.
• Keep out of reach of children and pets.
• Do not use after the expiration date on the packaging.